Johnson & Johnson (JNJ)

JNJ on New York Consolidated

105.55USD
19 Dec 2014
Price Change (% chg)

$-1.26 (-1.18%)
Prev Close
$106.81
Open
$106.63
Day's High
$107.39
Day's Low
$105.50
Volume
19,154,418
Avg. Vol
8,402,700
52-wk High
$109.49
52-wk Low
$86.09

JNJ

Chart for JNJ

About

Johnson & Johnson is a holding company engaged in the research and development, manufacture and sale of a broad range of products in the health care field. The business of Johnson & Johnson is conducted by more than 275 operating companies located in 60 countries, including the United States, which sell products in virtually all... (more)

Overall

Beta: 0.56
Market Cap (Mil.): $295,446.09
Shares Outstanding (Mil.): 2,799.11
Dividend: 0.70
Yield (%): 2.65

Financials

  JNJ Industry Sector
P/E (TTM): 17.47 37.83 38.47
EPS (TTM): 6.04 -- --
ROI: 16.48 18.99 18.25
ROE: 23.66 19.75 19.13
Search Stocks

Galapagos loses partner on inflammatory bowel drug

BRUSSELS - Belgian biotech group Galapagos said on Tuesday that its research partner Janssen Pharmaceutica, a unit of Johnson & Johnson, had pulled out of a program to develop a new drug to treat bowel disease.

16 Dec 2014

Galapagos loses partner on inflammatory bowel drug

BRUSSELS, Dec 16 - Belgian biotech group Galapagos said on Tuesday that its research partner Janssen Pharmaceutica, a unit of Johnson & Johnson, had pulled out of a programme to develop a new drug to treat bowel disease.

16 Dec 2014

Novartis psoriasis drug tops J&J's Stelara in late-stage study

ZURICH - Novartis said on Friday its experimental psoriasis drug Cosentyx was better at clearing the rough skin patches associated with the disease than Johnson & Johnson's Stelara.

12 Dec 2014

Novartis psoriasis drug tops J&J's Stelara in late-stage study

ZURICH, Dec 12 - Novartis said on Friday its experimental psoriasis drug Cosentyx was better at clearing the rough skin patches associated with the disease than Johnson & Johnson's Stelara.

12 Dec 2014

U.S. appeals court tosses $176 mln award for Covidien in patent case

- The top U.S. patent appeals court has thrown out a $176 million award for healthcare company Covidien Plc in a dispute with a Johnson & Johnson subsidiary over surgical instruments.

04 Dec 2014

U.S. appeals court tosses $176 million award for Covidien in patent case

- The top U.S. patent appeals court has thrown out a $176 million award for healthcare company Covidien Plc in a dispute with a Johnson & Johnson subsidiary over surgical instruments.

04 Dec 2014

U.S. appeals court tosses $176 mln award for Covidien in patent case

Dec 4 - The top U.S. patent appeals court has thrown out a $176 million award for healthcare company Covidien Plc in a dispute with a Johnson & Johnson subsidiary over surgical instruments.

04 Dec 2014

UPDATE 1-Market Chatter-Corporate finance press digest

Dec 4 - The following corporate finance-related stories were reported by media:

04 Dec 2014

Market Chatter- Corporate finance press digest

Dec 4 - The following corporate finance-related stories were reported by media:

03 Dec 2014

Exclusive: J&J hires Goldman to explore sale of Splenda - sources

NEW YORK/LONDON - U.S. healthcare company Johnson & Johnson has hired Goldman Sachs to explore a sale of its artificial sweetener brand Splenda, sources familiar with the matter told Reuters.

03 Dec 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks